PE104499A1 - Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes - Google Patents

Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes

Info

Publication number
PE104499A1
PE104499A1 PE1998000535A PE00053598A PE104499A1 PE 104499 A1 PE104499 A1 PE 104499A1 PE 1998000535 A PE1998000535 A PE 1998000535A PE 00053598 A PE00053598 A PE 00053598A PE 104499 A1 PE104499 A1 PE 104499A1
Authority
PE
Peru
Prior art keywords
insulin
diabetes
treatment
tiazolidindiona
pharmaceutical composition
Prior art date
Application number
PE1998000535A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE104499A1 publication Critical patent/PE104499A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE1998000535A 1997-06-18 1998-06-18 Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes PE104499A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9712866.4A GB9712866D0 (en) 1997-06-18 1997-06-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
PE104499A1 true PE104499A1 (es) 2000-01-13

Family

ID=10814527

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000535A PE104499A1 (es) 1997-06-18 1998-06-18 Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes

Country Status (30)

Country Link
EP (1) EP0999837A1 (no)
JP (1) JP2002504138A (no)
KR (1) KR20010013843A (no)
CN (1) CN1133431C (no)
AP (1) AP1287A (no)
AR (2) AR015894A1 (no)
AU (1) AU8216398A (no)
BG (1) BG104059A (no)
BR (1) BR9810444A (no)
CA (1) CA2294141A1 (no)
CO (1) CO4940454A1 (no)
DZ (1) DZ2521A1 (no)
EA (1) EA004800B1 (no)
GB (1) GB9712866D0 (no)
HU (1) HUP0003260A3 (no)
ID (1) ID23951A (no)
IL (1) IL133143A0 (no)
IN (1) IN189723B (no)
MA (1) MA26511A1 (no)
NO (1) NO996265D0 (no)
OA (1) OA11517A (no)
PE (1) PE104499A1 (no)
PL (1) PL343123A1 (no)
SK (1) SK179399A3 (no)
TR (1) TR199903095T2 (no)
TW (1) TW587937B (no)
UA (1) UA70299C2 (no)
UY (1) UY25050A1 (no)
WO (1) WO1998057636A1 (no)
ZA (1) ZA985237B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
BR0009934A (pt) 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
EP1849475A1 (en) * 1999-06-21 2007-10-31 Eli Lilly & Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
WO2001000223A2 (en) * 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
US6468507B1 (en) * 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
GB0023970D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US6531461B1 (en) 2001-06-04 2003-03-11 Louis Obyo Obyo Nelson Medicament for the treatment of diabetes
US20020198203A1 (en) * 2001-06-07 2002-12-26 Wyeth Combination of a PTPase inhibitor and a thiazolidinedione agent
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
DE60317365T2 (de) 2002-11-08 2008-08-21 F. Hoffmann-La Roche Ag Substituierte 4-alkoxyoxazol derivate als ppar agonisten
US7264813B2 (en) * 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN102389427A (zh) * 2011-10-10 2012-03-28 成都恒瑞制药有限公司 含有罗格列酮和盐酸西替利嗪的固体口服制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE376829T1 (de) * 1993-09-15 2007-11-15 Daiichi Sankyo Co Ltd Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm)
WO1997005875A2 (en) * 1995-08-10 1997-02-20 Warner-Lambert Company A method of reducing the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus
KR19990045756A (ko) * 1995-09-18 1999-06-25 윌리암 엘. 레스페스 Ｒｘｒ 작용제를 이용하는 ｎｉｄｄｍ 치료 방법

Also Published As

Publication number Publication date
CN1133431C (zh) 2004-01-07
TW587937B (en) 2004-05-21
AR015894A1 (es) 2001-05-30
KR20010013843A (ko) 2001-02-26
IN189723B (no) 2003-04-19
EP0999837A1 (en) 2000-05-17
JP2002504138A (ja) 2002-02-05
NO996265L (no) 1999-12-17
WO1998057636A1 (en) 1998-12-23
SK179399A3 (en) 2000-11-07
BG104059A (en) 2000-10-31
HUP0003260A2 (hu) 2001-05-28
ZA985237B (en) 2000-02-17
UY25050A1 (es) 2000-09-29
AU8216398A (en) 1999-01-04
HUP0003260A3 (en) 2001-12-28
TR199903095T2 (xx) 2000-08-21
PL343123A1 (en) 2001-07-30
AR012997A1 (es) 2000-11-22
EA004800B1 (ru) 2004-08-26
ID23951A (id) 2000-06-08
AP9901718A0 (en) 1999-12-31
AP1287A (en) 2004-06-26
OA11517A (en) 2004-02-04
EA200000042A1 (ru) 2000-08-28
CO4940454A1 (es) 2000-07-24
NO996265D0 (no) 1999-12-17
BR9810444A (pt) 2000-09-05
UA70299C2 (en) 2004-10-15
MA26511A1 (fr) 2004-12-20
CN1260715A (zh) 2000-07-19
GB9712866D0 (en) 1997-08-20
DZ2521A1 (fr) 2003-02-08
IL133143A0 (en) 2001-03-19
CA2294141A1 (en) 1998-12-23

Similar Documents

Publication Publication Date Title
PE83199A1 (es) Composicion farmaceutica de tiazolidinadiona y biguanida para el tratamiento de la diabetes
PE104499A1 (es) Composicion farmaceutica de tiazolidindiona e insulina para el tratamiento de la diabetes
ES2071339T3 (es) Agentes hipoglicemicos e hipocolesterolemicos de oxazolidindiona.
WO2001000223A3 (en) Multiple agent diabetes therapy
ATE273996T1 (de) Zusammensetzung zur therapie von diabetes mellitus und fettsucht
EP0861666A3 (en) Pharmaceutical composition for use in treatment of diabetes
BR0107564A (pt) Composição de gliburida
PE99599A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
KR950703953A (ko) 2-아미노-6-n-프로필아미노-4, 5, 6, 7-테트라하이드로벤조티아졸(프라미펙솔)의 항우울제로서의 용도(Use of 2-amino-6-n-propylamino-4, 5, 6, 7-tetrahydrobenzothiazole (pramipexol)as an antidepressant drug)
BR9813801A (pt) Composto, composição farmacêutica, e, processos para o tratamento, controle, ou prevenção, em um mamìfero, de diabete mellitus, de hiperglicemia, de hiperlipidemia, de obesidade, de hipercolesterolemia, e, de hipertrigliceridemia.
SE9702305D0 (sv) New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
PE99499A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
MY135973A (en) Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative
ATE277907T1 (de) Blutzuckersenkende und lipidsenkende verbindungen
PE99799A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
PE89199A1 (es) Composicion farmaceutica de tiazolidinadiona y un inhibidor de alfa glucosidasa para el tratamiento de la diabetes
PE108199A1 (es) Composicion farmaceutica de tiazolidindiona y sulfonilurea
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
EA200300345A1 (ru) Гидрохлоридная соль 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона
EA200300005A1 (ru) Соль тиазолидиндиона для лечения сахарного диабета
CY1107767T1 (el) Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο
TR200103041T2 (tr) Yeni farmas”tik maddeler.
PT1446404E (pt) Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos
GB0021784D0 (en) Novel pharmaceutical
BR9813037A (pt) Composto, processo para sua preparação, uso do mesmo, preparação farmacêutica, e, combinação desta com pelo menos uma outra substância ativa

Legal Events

Date Code Title Description
FC Refusal